Trinity Biotech (TRIB) to Release Earnings on Wednesday

Trinity Biotech (NASDAQ:TRIB) is expected to release its Q4 2025 resultson Wednesday, April 8th. Analysts expect Trinity Biotech to post earnings of ($0.32) per share and revenue of $15.00 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, April 6, 2026 at 9:30 AM ET.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings data on Friday, January 2nd. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.48) by $1.16. The business had revenue of $9.20 million during the quarter, compared to analysts’ expectations of $10.50 million. On average, analysts expect Trinity Biotech to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Trinity Biotech Trading Down 3.7%

NASDAQ TRIB opened at $0.54 on Wednesday. The business’s 50-day moving average price is $0.74 and its 200 day moving average price is $0.89. Trinity Biotech has a twelve month low of $0.48 and a twelve month high of $3.44.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Trinity Biotech stock. Perceptive Advisors LLC purchased a new stake in Trinity Biotech PLC (NASDAQ:TRIB) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 1,790,000 shares of the company’s stock, valued at approximately $1,164,000. Perceptive Advisors LLC owned approximately 9.92% of Trinity Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 78.97% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trinity Biotech in a research note on Wednesday, March 25th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce”.

About Trinity Biotech

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.